This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Law Office Of Joseph Klein Investigates Possible Breach Of Fiduciary Duty By The Board Of Abraxis BioSciences Inc. - ABII

The Law Office of Joseph Klein, Esq. is investigating the Board of Directors of Abraxis BioSciences Inc. (“Abraxis” or the “Company”) (NasdaqGS: ABII) for possible breaches of fiduciary duty and other violations of state law in connection with the Board’s attempt to sell the Company to Celgene Corporation ("Celgene") (NasdaqGS: CELG) for $58 in cash and 0.2617 shares of Celgene stock for each Abraxis share owned by shareholders. The proposed transaction values Abraxis stock at approximately $71.93 per share for a total transaction value of approximately $2.9 billion, net of cash. Each Abraxis shareholder will also receive one tradable contingent value right for each share that entitles its holder to receive payments for future regulatory milestones and commercial royalties.

The investigation focuses on whether Abraxis’ Board breached its fiduciary duties to stockholders by failing to adequately shop the Company before entering into this transaction and whether Celgene is underpaying for Abraxis shares, thus unlawfully harming Abraxis’ stockholders.

If you own common stock in Abraxis and wish to obtain additional information, please contact Joseph Klein, Esq. via email at jk@kleinstocklaw.com, by telephone at (718) 947-0005 or visit http://kleinstocklaw.com/abraxis-bioscience.html

Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation.



Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
AAPL $128.70 -0.19%
FB $78.81 -0.23%
GOOG $540.78 0.54%
TSLA $230.51 1.98%
YHOO $42.04 -1.11%

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs